Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach

Abstract Background Colorectal cancer (CRC) is a prevalent malignancy worldwide, associated with significant morbidity and mortality. Cyclin-dependent kinase 1 (CDK1) plays a crucial role in cell cycle regulation and has been implicated in various cancers. This study aimed to evaluate the prognostic...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiemiao Shen, Xing Gong, Haili Ren, Xia Tang, Hairong Yu, Yilu Tang, Shen Chen, Minghui Ji
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-13448-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594645821947904
author Jiemiao Shen
Xing Gong
Haili Ren
Xia Tang
Hairong Yu
Yilu Tang
Shen Chen
Minghui Ji
author_facet Jiemiao Shen
Xing Gong
Haili Ren
Xia Tang
Hairong Yu
Yilu Tang
Shen Chen
Minghui Ji
author_sort Jiemiao Shen
collection DOAJ
description Abstract Background Colorectal cancer (CRC) is a prevalent malignancy worldwide, associated with significant morbidity and mortality. Cyclin-dependent kinase 1 (CDK1) plays a crucial role in cell cycle regulation and has been implicated in various cancers. This study aimed to evaluate the prognostic value of CDK1 in CRC and to identify traditional Chinese medicines (TCM) that can target CDK1 as potential treatments for CRC. Methods The expression and prognostic value of CDK1 were analyzed through TCGA, GEO, GEPIA, UALCAN and HPA databases. An ESTIMATE analysis was applied to estimate the proportions of stromal and immune cells in tumor samples. GO and KEGG enrichment analyses were performed to clarify the functional roles of CDK1-related genes. CCK-8, colony formation, cell migration, cell invasion, and wound healing assays were employed to explore tumor-promoting role of CDK1. Molecular docking, cellular thermal shift, and isothermal dose-response assays were employed to identify potential inhibitors of CDK1. Results CDK1 was highly expressed in CRC and associated with a poorer prognosis. The expression of CDK1 was also correlated with the levels of immune cells infiltration. CDK1-related genes were primarily involved in the cell cycle and the P53 signaling pathway. Knockdown of CDK1 inhibited the proliferation, migration, and invasion of CRC cells in vitro. Furthermore, Eriocitrin emerged as a potential inhibitor, exerting its anti-tumor effects by targeting and inhibiting CDK1 activity. Conclusion CDK1 plays a critical role in CRC prognosis. Eriocitrin, a potential CDK1 inhibitor derived from TCM, highlights a promising new therapeutic strategy for CRC treatment.
format Article
id doaj-art-b6c91f2645cc49d382403121ef8bd72a
institution Kabale University
issn 1471-2407
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-b6c91f2645cc49d382403121ef8bd72a2025-01-19T12:26:54ZengBMCBMC Cancer1471-24072025-01-0125111710.1186/s12885-025-13448-xIdentification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approachJiemiao Shen0Xing Gong1Haili Ren2Xia Tang3Hairong Yu4Yilu Tang5Shen Chen6Minghui Ji7Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityDepartment of Environment Health, Nanjing Medical University Affiliated Nanjing Municipal Center for Disease Control and PreventionDepartment of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityDepartment of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityDepartment of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityDepartment of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityDepartment of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityDepartment of Fundamental and Community Nursing, School of Nursing, Nanjing Medical UniversityAbstract Background Colorectal cancer (CRC) is a prevalent malignancy worldwide, associated with significant morbidity and mortality. Cyclin-dependent kinase 1 (CDK1) plays a crucial role in cell cycle regulation and has been implicated in various cancers. This study aimed to evaluate the prognostic value of CDK1 in CRC and to identify traditional Chinese medicines (TCM) that can target CDK1 as potential treatments for CRC. Methods The expression and prognostic value of CDK1 were analyzed through TCGA, GEO, GEPIA, UALCAN and HPA databases. An ESTIMATE analysis was applied to estimate the proportions of stromal and immune cells in tumor samples. GO and KEGG enrichment analyses were performed to clarify the functional roles of CDK1-related genes. CCK-8, colony formation, cell migration, cell invasion, and wound healing assays were employed to explore tumor-promoting role of CDK1. Molecular docking, cellular thermal shift, and isothermal dose-response assays were employed to identify potential inhibitors of CDK1. Results CDK1 was highly expressed in CRC and associated with a poorer prognosis. The expression of CDK1 was also correlated with the levels of immune cells infiltration. CDK1-related genes were primarily involved in the cell cycle and the P53 signaling pathway. Knockdown of CDK1 inhibited the proliferation, migration, and invasion of CRC cells in vitro. Furthermore, Eriocitrin emerged as a potential inhibitor, exerting its anti-tumor effects by targeting and inhibiting CDK1 activity. Conclusion CDK1 plays a critical role in CRC prognosis. Eriocitrin, a potential CDK1 inhibitor derived from TCM, highlights a promising new therapeutic strategy for CRC treatment.https://doi.org/10.1186/s12885-025-13448-xColorectal cancerCyclin-dependent kinase 1PrognosisMolecular dockingEriocitrin
spellingShingle Jiemiao Shen
Xing Gong
Haili Ren
Xia Tang
Hairong Yu
Yilu Tang
Shen Chen
Minghui Ji
Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
BMC Cancer
Colorectal cancer
Cyclin-dependent kinase 1
Prognosis
Molecular docking
Eriocitrin
title Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
title_full Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
title_fullStr Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
title_full_unstemmed Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
title_short Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
title_sort identification and validation of cdk1 as a promising therapeutic target for eriocitrin in colorectal cancer a combined bioinformatics and experimental approach
topic Colorectal cancer
Cyclin-dependent kinase 1
Prognosis
Molecular docking
Eriocitrin
url https://doi.org/10.1186/s12885-025-13448-x
work_keys_str_mv AT jiemiaoshen identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT xinggong identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT hailiren identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT xiatang identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT hairongyu identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT yilutang identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT shenchen identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach
AT minghuiji identificationandvalidationofcdk1asapromisingtherapeutictargetforeriocitrinincolorectalcanceracombinedbioinformaticsandexperimentalapproach